Indoco Remedies Limited · NSE:INDOCO
Indoco Remedies — Q2/H1-FY25 Earnings Presentation
19 slides from Indoco Remedies's earnings presentation, Oct 24, 2024
Slide 1: Exchange filing cover letter: Investor Presentation
Date: 24th October, 2024 To To The Listing Department The Listing Department National Stock Exchange of India Limited Bombay Stock Exchange Limited Exchange Plaza, Floor 25, P. J. Towers, Bandra – Kurla Complex Dalal Street, Bandra (East) Mumbai – 400 001 Mumbai – 400 051 Stock Code : 532612 Stock C
Slide 2: Earnings Presentation Q2/H1-FY25
Indoco Remedies Limited E A R N I N G S P R E S E N TAT I O N Q2/H1-FY25
Slide 3: Snapshot
S N A P S H OT 7 Decades 11 Manufacturing Facilities EMPLOYEE of Presence in India 7 FDF Plants STRENGTH >6000 4 API Plants R&D facility (400+ scientists) Ranked 31st Development of complex Footprint (IQVIA Sep’24) ophthalmics & injectables across 55+ countries Ranked 23rd NDDS & New Platform and ex
Slide 4: Company Overview
C O M PA N Y O V E RV I E W • In 1945, our founder, Late Mr. Govind Ramnath Kare founded ‘Indo- Continental Trading Company’, the principal business of which was to import STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) pharmaceutical formulations from Europe and distribute them in the Western Indi
Slide 5: Geographical Footprint
G EO G R A P H I C A L F O OT P R I N T Baddi, Himachal Pradesh (2) Canada UK Netherlands Germany PolandBelarus France Ukraine Italy USA Spain Iraq Portugal Iran Lebanon Kuwait Jordan Bahrain Libya Algeria Egypt Qatar UAE Myanmar Taiwan Saudi Arabia Mauritania Mali Oman Senegal Niger Chad Yemen Thai
Slide 6: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 7: Q2/H1-FY25 Highlights
Q2/H1-FY25 HIGHLIGHTS Q2-FY25 Financial Highlights H1 - FY25 Financial Highlights INR 3,946 Mn INR 529 Mn 13.4 % INR 7,888 Mn INR 1,044 Mn 13.2 % Operating Income Operating EBITDA Operating EBITDA Operating Income Operating EBITDA Operating EBITDA Margins Margins INR 128 Mn 3.2 % INR 1.39 /SHARE INR
Slide 8: Q2-FY25 Geographical Breakup
Q2-FY25 GEOGRAPHICAL BREAKUP REGULATED MARKETS EMERGING MARKETS Netherlands Other Emerging 3% Markets, 1% Others 5% Asia, 8% Germany UK LATAM, 23% 20% 44% FWA, 51% USA Africa, 17% 28% 7
Slide 9: Quarterly KPI - Formulation Business
Q UA R T E R LY K P I - F O R M U L AT I O N B U S I N E S S TOTAL REVENUE (INR MN) DOMESTIC REVENUE (INR MN) DOMESTIC REVENUE (INR MN) (IRL) (IRL + WRPL) 4,230 3,608 3,573 2,556 2,281 2,346 2,281 2,241 2,002 Q2-FY25 Q2-FY24 Q1-FY25 Q2-FY25 Q2-FY24 Q1-FY25 Q2-FY25 Q2-FY24 Q1-FY25 REGULATED MARKET RE
Slide 10: Formulation Business – India Therapeutic & Brand Performance
F O R M U L AT I O N B U S I N E S S – I N D I A T H E R A P E U T I C & B R A N D P E R F O R M A N C E INDIA THEREPEUTIC SEGMENT PERFORMANCE PARTICULARS (INR MN) Q2FY25 Q2FY24 Y-o-Y (%) Q1FY25 Q-o-Q (%) GASTRO INTESTINAL 406 320 27 447 -9 ANTI-INFECTIVES 394 351 12 244 61 STOMATOLOGICALS * 552 521
Slide 11: Quarterly KPI – API/Allied Service
Q UA R T E R LY K P I – A P I /A L L I E D S E R V I C E DOMESTIC REVENUE (INR MN) INTERNATIONAL REVENUE (INR MN) TOTAL REVENUE (API) (INR MN) 358 301 312 214 237 155 203 88 75 Q2-FY25 Q2-FY24 Q1-FY25 Q2-FY25 Q2-FY24 Q1-FY25 Q2-FY25 Q2-FY24 Q1-FY25 TOTAL REVENUE(Allied Services) (INR MN) 64 57 36 Q2
Slide 12: Business Highlights – Q2-FY25
BUSINESS HIGHLIGHTS – Q2-FY25 • On 23rd August, as India celebrated its National Space Day, Indoco celebrated 77 years of providing quality medicines & building healthier communities • Indoco Remedies received final ANDA approval from the USFDA for Lofexidine Tablets 0.18 mg with Competitive Generic
Slide 13: Quarterly Standalone Income Statement
Q UA R T E R LY S TA N D A LO N E I N C O M E S TAT E M E N T PARTICULARS (INR Mn) Q2-FY25 Q2-FY24 Y-o-Y (%) Q1-FY25 Q-o-Q (%) Operational Revenue 3,946 4,652 -15 3,942 Operating Expenses 3,437 4,010 -14 3,499 -2 EBITDA 529 724 -27 516 3 EBITDA Margin (%) 13.4% 15.6% 13.1% Depreciation and Amortisat
Slide 14: YTD Standalone Income Statement
Y T D S TA N D A LO N E I N C O M E S TAT E M E N T PARTICULARS (INR Mn) H1 FY25 H1 FY24 Y-o-Y (%) Operational Revenue 7,888 8,784 -10 Operating Expenses 6,935 7,609 -9 EBITDA 1,044 1,353 -23 EBITDA Margin (%) 13.2% 15.4% Depreciation and amortisation 486 413 18 Finance costs 267 159 68 Other Income
Slide 15: Historical Standalone Financial Performance
H I S TO R I C A L S TA N D A LO N E F I N A N C I A L P E R F O R M A N C E PARTICULARS (INR Mn) FY22 FY23 FY24 H1 FY25 Operational Revenue 15,027 16,381 17,620 7,888 Operating Expenses 12,127 13,818 15,328 6,935 EBITDA 3,270 2,849 2,580 1,044 EBITDA Margin (%) 21.8% 17.4% 14.6% 13.2% Depreciation
Slide 16: Historical Standalone Financial Highlights
H I S TO R I C A L S TA N D A LO N E F I N A N C I A L H I G H L I G H T S OPERATIONAL REVENUE (INR Mn) EBIDTA (INR Mn) & EBITDA PAT (INR Mn) & PAT MARGINS (%) 17,620 MARGINS (%) 16,381 15,027 1,545 3,270 1,414 2,849 2,580 1,166 7888 1044 21.8% 17.4% 277 14.6% 10.3% 13.2% 8.6% 6.6% 3.5% FY22 FY23 FY
Slide 17: Capital Market Information
C A P I TA L M A R K E T I N F O R M AT I O N 40.00% SHARE PRICE PERFORMANCE 30.00% 20.00% 10.00% 0.00% -10.00% -20.00% Oct-23 Nov-23 Dec-23 Feb-24 Mar-24 May-24 Jun-24 Aug-24 Sep-24 SENSEX INDOCO MARKET DATA (Rs.) AS ON 30th SEPT, 2024 SHAREHOLDING PATTERN AS ON 30th SEPT, 2024 Face Value 2.0 FII D
Slide 18: Disclaimer
DISCLAIMER Indoco Remedies Limited Disclaimer: No representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in
Slide 19: Thank You
THANK YOU